FBInvestor
Stocks / Enlivex Therapeutics Ltd
Institutional Ownership

Enlivex Therapeutics Ltd

CUSIP M4130Y106COMQ1 2026

13D / 13G Filings
5
Schedule 13D/13G on record
Beneficial Filers
3
Distinct reporting persons
Largest Stake
10.0%
Max % of class reported
Institutional Holders
35
13F filers (latest quarter)

Beneficial Owners — Schedule 13D / 13G

5 filings · latest Aug 14, 2025

Export CSV — Pro
#FiledReporting PersonForm% of ClassSharesFiling
1Aug 14, 2025Armistice Capital, LLC13G/A5.0%209.3KSEC
2May 15, 2025Armistice Capital, LLC13G/A7.5%1.78MSEC
3Feb 14, 2025Armistice Capital, LLC13G/A9.8%2.21MSEC
4Nov 14, 2024Armistice Capital, LLC13G10.0%2.18MSEC
5Feb 14, 2020Nussbaum Ran13G/A0.5%46.8KSEC

Top Institutional Holders (13F)

Largest reported positions · latest quarter

View all →
#FundSharesValue
1Diametric Capital, LP1.48M$1.38M
2Ark Investment Management LLC628.3K$584.4K
3Prelude Capital Management, LLC225.7K$210.0K
4Two Sigma Investments, LP146.4K$136.2K
5Ubs Group AG138.3K$128.6K
6Bank Of America Corp /De/130.4K$121.3K
7Renaissance Technologies LLC128.2K$119.2K
8Jpmorgan Chase & Co125.9K$113.4K
9Goldman Sachs Group Inc102.1K$95.0K
10Xtx Topco Ltd100.4K$93.3K